Meilleure Health International Industry Group Limited (HK:2327)
:2327
Want to see HK:2327 full AI Analyst Report?
Top Page
Meilleure Health International Industry Group Limited
(2327)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$0.29
▲(4.29% Upside)
Action:Reiterated
Date:05/02/26
The score is held back primarily by weak and volatile cash flow and deteriorating operating performance despite strong headline net income margins. Technicals are moderately supportive with the price above key moving averages, and valuation appears reasonable with a mid-range P/E and modest yield.
Positive Factors
High gross margins
Sustained gross margins near 57–62% indicate structural pricing power or a high-margin business mix. This buffer supports long-term margin sustainability, allowing the company to absorb SG&A or investment spending and helps preserve profitability if revenue stabilizes.
Negative Factors
Sharp revenue decline
A near-28% revenue drop and consecutive years of contraction undermine scale economics and market position. Persistent top-line erosion reduces ability to leverage fixed costs, threatens long-run competitiveness, and limits resources for product, sales, or market investment.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 57–62% indicate structural pricing power or a high-margin business mix. This buffer supports long-term margin sustainability, allowing the company to absorb SG&A or investment spending and helps preserve profitability if revenue stabilizes.
Read all positive factors
Meilleure Health International Industry Group Limited (2327) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.19B
Dividend Yield2%
Average Volume (3M)3.52M
Price to Earnings (P/E)28.5
Beta (1Y)0.22
Revenue Growth-27.94%
EPS Growth18.99%
CountryHK
Employees46
SectorIndustrials
Sector Strength72
IndustryConglomerates
Share Statistics
EPS (TTM)<0.01
Shares Outstanding4,093,756,600
10 Day Avg. Volume6,054,000
30 Day Avg. Volume3,517,820
Financial Highlights & Ratios
PEG Ratio1.61
Price to Book (P/B)0.87
Price to Sales (P/S)29.64
P/FCF Ratio-21.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Meilleure Health International Industry Group Limited Business Overview & Revenue Model
Company Description
Meilleure Health International Industry Group Limited, an investment holding company, engages in industrial hemp, healthcare-related, trading, agency service, property investment and leasing, and property development businesses in Hong Kong, the P...
Meilleure Health International Industry Group Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
66
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 36.52M | 50.68M | 129.30M | 119.89M | 253.03M |
| Gross Profit | 22.63M | 28.91M | 78.09M | 66.76M | 100.93M |
| EBITDA | -8.97M | 56.52M | 71.38M | 55.46M | 108.73M |
| Net Income | 37.98M | 32.48M | 40.83M | 17.82M | 60.32M |
Balance Sheet | |||||
| Total Assets | 1.82B | 1.67B | 1.70B | 1.71B | 1.74B |
| Cash, Cash Equivalents and Short-Term Investments | 20.18M | 29.94M | 106.31M | 210.99M | 380.39M |
| Total Debt | 380.96M | 303.06M | 297.06M | 249.13M | 170.42M |
| Total Liabilities | 567.34M | 467.29M | 442.89M | 384.18M | 306.35M |
| Stockholders Equity | 1.25B | 1.20B | 1.25B | 1.32B | 1.43B |
Cash Flow | |||||
| Free Cash Flow | -50.60M | 188.62M | -137.32M | 42.10M | -89.79M |
| Operating Cash Flow | -50.02M | 188.75M | -136.49M | 43.15M | -83.27M |
| Investing Cash Flow | 14.64M | -253.98M | 53.72M | -134.76M | 161.56M |
| Financing Cash Flow | 18.07M | -6.39M | -18.90M | 41.93M | -38.22M |
Meilleure Health International Industry Group Limited Technical Analysis
Positive
0.28
Price Trends
0.27
Positive
0.27
Positive
0.27
Positive
Market Momentum
<0.01
Positive
58.49
Neutral
60.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2327, the sentiment is Positive. The current price of 0.28 is below the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.27, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 58.49 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2327.
Meilleure Health International Industry Group Limited Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$607.12M | 2.30 | 50.27% | ― | 30.98% | 69.07% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
55 Neutral | HK$1.19B | 28.49 | 3.08% | 2.00% | -27.94% | 18.99% | |
52 Neutral | HK$974.39M | 0.33 | -194.26% | ― | -64.04% | 1.66% | |
46 Neutral | HK$1.23B | 1.27 | -3.46% | 3.80% | 10.38% | 7.39% | |
44 Neutral | HK$415.54M | -6.11 | -13.05% | ― | -26.45% | 33.00% |
* Industrials Sector Average
HK:2327
Meilleure Health International Industry Group Limited
0.29
<0.01
2.47%
HK:0025
Chevalier International Holdings Limited
4.07
0.30
7.96%
HK:2322
Hong Kong ChaoShang Group Ltd.
0.10
-0.36
-78.26%
HK:0474
Aceso Life Science Group Limited
0.11
0.09
440.00%
HK:8162
Loco Hong Kong Holdings Ltd
0.61
0.07
12.96%
Meilleure Health International Industry Group Limited Corporate Events
Meilleure Health Sets 2026 AGM to Approve Dividend, Board Mandates and Share Issuance Powers
Apr 28, 2026
Meilleure Health International Industry Group Limited has convened its annual general meeting for 26 June 2026 in Hong Kong, where shareholders will review the audited financial statements for the year ended 31 December 2025 and vote on a proposed...
Meilleure Health Wins Unanimous Minority Backing for Equity Transfer and 2026 Share Award Plan
Apr 21, 2026
Meilleure Health International Industry Group Limited secured shareholder approval at a special general meeting in Hong Kong on 21 April 2026 for a discloseable and connected transaction under an Equity Interest Transfer Agreement and for the adop...
Meilleure Health Lifts 2025 Profit Despite Revenue Decline
Mar 27, 2026
Meilleure Health International Industry Group reported revenue of HK$36.5 million for 2025, down from HK$50.7 million a year earlier, but maintained a solid gross profit of HK$22.6 million as cost of goods sold and services fell. The company also ...
Meilleure Health Announces Final Cash Dividend for 2025
Mar 27, 2026
Meilleure Health International Industry Group Limited has proposed a final ordinary cash dividend of HKD 0.004 per share for the financial year ended 31 December 2025, subject to shareholder approval at a meeting scheduled for 26 June 2026. The di...
Meilleure Health to Forfeit Unclaimed 2017 Interim Dividends After Six Years
Mar 27, 2026
Meilleure Health International Industry Group Limited has announced that any unclaimed interim dividend for the six months ended 30 June 2017, declared at HK$0.006 per share and originally payable on 31 October 2017, will be forfeited after remain...
Meilleure Health Calls April 2026 SGM on Equity Transfer and New Share Award Scheme
Mar 27, 2026
Meilleure Health International Industry Group Limited has called a special general meeting in Hong Kong on 21 April 2026 to seek shareholder approval for an equity interest transfer agreement and the related authorisation for directors to execute ...
Meilleure Health Plans 10-Year Share Award Scheme to Align Stakeholder Interests
Mar 24, 2026
Meilleure Health International Industry Group Limited plans to adopt a new 2026 Share Award Scheme, which will run for 10 years once approved and will be treated as a share scheme under Chapter 17 of the Hong Kong Listing Rules. The scheme is desi...
Meilleure Health Sets March Board Meeting to Approve 2025 Final Results and Consider Dividend
Mar 12, 2026
Meilleure Health International Industry Group Limited has scheduled a board meeting for 27 March 2026 to review and approve the consolidated final results for the year ended 31 December 2025. The board will also consider whether to recommend a fin...
Meilleure Health Delays Dispatch of Circular on Equity Interest Transfer
Mar 6, 2026
Meilleure Health International Industry Group Limited has announced a further delay in sending a shareholder circular related to a disclosable and connected transaction involving an equity interest transfer agreement. The circular, which will incl...
Meilleure Health Delays Despatch of Circular on Connected Equity Transfer Deal
Feb 6, 2026
Meilleure Health International Industry Group Limited has announced a delay in sending to shareholders a circular relating to a previously disclosed equity interest transfer agreement that constitutes a discloseable and connected transaction. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.